Upper age limit of =<  years of age for medullary thyroid carcinoma (MTC), renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC)
No prior systemic therapy for clear cell renal cancer
Histological or cytological diagnosis of renal cell cancer with a clear-cell component
Renal cell carcinoma (clear cell predominant type);
For papillary renal cell carcinoma patients, the following are required:
Documented local confirmation of renal cell carcinoma with a predominantly papillary growth pattern.
Histologically-confirmed renal cell carcinoma (any histologic subtype) without evidence of distant metastatic disease
Biopsy/pathology-proven clear cell renal cell carcinoma (CCRCC) with metastases
Histologically confirmed metastatic renal cell carcinoma with predominantly clear cell histology
Localized clear cell renal carcinoma without evidence of distant metastases
Advanced Renal Cell Carcinoma
Patient has histologically confirmed locally recurrent or metastatic predominantly clear cell renal cell carcinoma.
Renal cell carcinoma without any clear (conventional) cell component
Histological confirmation of renal cell carcinoma (RCC) (any histology)
Histologically confirmed renal cell carcinoma (RCC)
Histological confirmation of renal cell carcinoma (RCC) with a predominantly (> %) clear cell component
Histological confirmation of renal cell carcinoma (RCC) with a clear-cell component
An archived tissue block with the subjects renal cell carcinoma must be identified prior to registration
Patients with imaging findings consistent with renal cell carcinoma
Pathologic diagnosis of metastatic renal cell carcinoma (RCC) with clear cell component with progression or intolerance to at least one prior systemic anti-angiogenic therapy (if a previous biopsy of metastatic site within the last  months exists and a review of stained slides shows it to be adequate then a pretreatment biopsy is not required)
Cohort C  Renal cell carcinoma (> pTb); must have radiologic suspicion or histological proof of clear cell renal cell carcinoma >=  cm with no evidence of metastatic disease; patient with any degree of tumor extension into the renal vein are not eligible; patients must be candidates for contrast-enhanced ultrasound (CEUS) imaging and agree to undergo this additional imaging technique
Patients must have histologically or cytologically confirmed clear cell renal cell carcinoma (RCC)
Prior systemic therapy for renal cell carcinoma
Documented pathologic diagnosis of RCC; all subtypes eligible including but not limited to clear cell, papillary, chromophobe, collecting duct carcinoma, medullary carcinoma, and unclassified categories; sarcomatoid and rhabdoid differentiation are allowed
If a previous biopsy of mass has been done, pathology must be consistent with renal cell carcinoma (RCC)
Patients must not have received prior anticancer therapy with bevacizumab, anti-CLTA-, or anti-PD for renal cell carcinoma; patients receiving any concomitant systemic therapy for renal cell cancer are excluded
RENAL CELL CARCINOMA (RCC) COHORT EXCLUSION CRITERIA: History of other malignancy with concern for renal metastasis and known allergy to technetium or sestamibi
Histological confirmation of non-clear cell renal cancer (including chromophilic [papillary], chromophobic, oncocytic, sarcomatoid, collecting duct [Bellini's duct]), translocation-type carcinoma or medullary renal cell carcinoma
Renal cell cancer
RENAL COHORT: Histological documentation of renal cell carcinoma with a clear cell component in the metastatic renal cell carcinoma cohort
Renal cell cancer
Adult with unresectable locally advanced or metastatic renal cell carcinoma with a clear cell component
Patients must have histologically confirmed renal cell carcinoma (of any subtype) containing any sarcomatoid features; there must be histologic confirmation by the treating center of either the primary or metastatic lesion
Renal medullary carcinoma
Renal medullary carcinoma
e. Renal Cell Carcinoma Have histologically confirmed diagnosis of predominant clear cell renal cell carcinoma.
Patient must have pathologically confirmed renal cell carcinoma with a clear cell component; pure papillary and chromophobe histologies are excluded; there must be pathologic confirmation of metastatic disease in the resected metastasectomy specimen
Documented histological or cytological diagnosis of renal cell carcinoma with a clear-cell component.
Patients must have histologically or cytologically confirmed renal cell carcinoma (clear cell or non-clear cell allowed, but collecting duct or medullary carcinomas excluded); patients must be considered pathologically either intermediate high risk or very high risk; patients must not have a history of distant metastases; patients with microvascular invasion of the renal vein of any grade or stage (as long as M) are also eligible
Histologically confirmed diagnosis of Renal Cell Carcinoma with a documented clear cell component (ccRCC)
Histologically confirmed diagnosis of advanced or metastatic clear cell or papillary renal cell carcinoma or histologically confirmed clear cell ovarian carcinoma.
Advanced Renal Cell Carcinoma
Evidence that the renal cell carcinoma is advanced or metastatic.
Patients with an International Metastatic Renal Cell Carcinoma Database Consortium (IMDC or Heng) score of  or less will be included; score greater than  will be excluded;  point each: requirement of systemic treatment for metastatic disease less than  year of original diagnosis of renal cell carcinoma, a serum calcium greater than , anemia, neutrophilia, thrombocytosis, ECOG performance status >= 
Renal Cell Carcinoma
The patient must have a pathologically confirmed diagnosis of clear cell (renal cell) carcinoma, which is currently Stage  disease.
Histologically confirmed, locally recurrent or metastatic clear cell renal cell carcinoma
Non clear cell renal cell carcinoma (RCC)
Documented pathologic diagnosis of renal cell carcinoma (RCC); all subtypes eligible including but not limited to clear cell, papillary, chromophobe, collecting duct carcinoma, medullary carcinoma, and unclassified categories; sarcomatoid and rhabdoid differentiation are allowed
Phase II: has had prior therapy for metastatic renal cell carcinoma.
Histological confirmation of renal cell carcinoma (RCC) with a clear-cell component
Histologically or cytologically-confirmed metastatic renal cell carcinoma of clear cell histology; prior nephrectomy is not a requirement for eligibility
Histologically or cytologically confirmed clear cell renal cell carcinoma (ccRCC); pathology report from the original diagnosis of renal cell carcinoma is acceptable; the component of conventional clear cell type > % is mandatory only if there is more than one cell type identified in the tumor tissue
Histologic confirmation of renal cell carcinoma (RCC) with clear-cell component
Patients must have histologically or cytologically confirmed renal cell carcinoma except medullary or collecting duct subtypes; sarcomatoid differentiation will be allowed
Patients without sarcoma, renal cell carcinoma, or melanoma
Radiographic evidence of nonmetastatic renal cell carcinoma
Histological verification of clear cell renal cell carcinoma (note: this will be confirmed post informed consent)
Histological or cytological confirmation of renal cell carcinoma (RCC) with a clear-cell component
Patients must have pathological diagnosis of renal cell carcinoma that is metastatic or surgically unresectable; the histology must be clear cell carcinoma or predominant clear cell carcinoma
Patients must have a diagnosis of a metastatic renal cell carcinoma with a >= % clear cell component
Histologically confirmed diagnosis of predominant clear cell renal cell carcinoma.
Patients with renal cell carcinoma less than  cm in maximum diameter, who are poor surgical candidates are eligible for randomization between SBRT and RFA\r\n* Renal cell carcinoma must be pathologically proven
Patients with renal cell carcinoma less than  cm in maximum diameter, patients with metastatic RCC who require local palliation or are progressing through systemic disease, patients who are poor surgical candidates and have tumor location not amenable to RFA, or patients who would prefer a noninvasive means of treatment are eligible for the non-randomized SBRT cohort\r\n* Renal cell carcinoma must be pathologically proven
Patients with bilateral renal cell carcinoma
Have had at least  prior systemic treatments for renal cell carcinoma (RCC)
Have a histologically confirmed diagnosis of predominant clear cell (conventional) Renal Cell Carcinoma (ccRCC).
Part B: Renal cell carcinoma (any histology)
Must have histologically confirmed renal cell carcinoma of any pathologic subtype.
Documented histological or cytological diagnosis of renal cell carcinoma with a clear-cell component
Patients must have histologically confirmed metastatic or unresectable renal cell carcinoma; predominant clear cell component is required; pure papillary and chromophobe renal cell carcinoma, collecting duct tumors and transitional cell carcinoma are not eligible
Histological or cytological proof of component (any percent) of clear cell RCC (renal cell carcinoma).
Histologically or cytologically confirmed diagnosis of metastatic clear-cell renal cell carcinoma (ccRCC)
Participants with histologically confirmed non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease. Participants must have one of the following subtypes of nccRCC: papillary, chromophobe, collecting duct carcinoma (CDC), renal medullary carcinoma (RMC), or unclassified.
Predominant clear cell renal cell carcinoma (RCC)
Cytologically or pathologically verified diagnosis of renal cell carcinoma (RCC)
RENAL CANCER: Histologically confirmed renal cell carcinoma (RCC)
If biopsy of mass has been done, pathology must be consistent with renal cell carcinoma (RCC)
Histologically confirmed renal cell carcinoma
Diagnosis of unresectable and/or metastatic clear cell renal cell carcinoma;  patients will be enrolled who have had no prior anti-angiogenic therapy;  patients will be enrolled who have had one prior anti-angiogenic therapy
Renal Cell Carcinoma: documented histological or cytological diagnosis of renal cell cancer with a clearcell or papillary component; progression following at least two prior lines of standard therapy including a checkpoint inhibitor and an anti-VEGFR inhibitor; archival tissue or fresh tumor biopsy
Patients must have metastatic renal cell carcinoma (RCC)
B-cell ALL